Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $270 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 84.3%

Neg 0% Neu 84.3% Pos 0%

Guggenheim analyst Vamil Divan reiterates Johnson & Johnson (NYSE:JNJ) with a Buy and maintains $270 price target.

Comments

No comments yet. Be the first!